Fulgent Genetics EBITDA Margin 2015-2024 | FLGT
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Fulgent Genetics (FLGT) over the last 10 years. The current EBITDA margin for Fulgent Genetics as of December 31, 2024 is .
| Fulgent Genetics EBITDA Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM EBITDA | EBITDA Margin |
| 2024-12-31 | $0.28B | $-0.05B | -18.73% |
| 2024-09-30 | $0.28B | $-0.07B | -24.46% |
| 2024-06-30 | $0.29B | $-0.05B | -17.53% |
| 2024-03-31 | $0.29B | $-0.05B | -17.71% |
| 2023-12-31 | $0.29B | $-0.05B | -18.28% |
| 2023-09-30 | $0.29B | $-0.05B | -18.47% |
| 2023-06-30 | $0.31B | $-0.05B | -15.26% |
| 2023-03-31 | $0.37B | $-0.01B | -3.01% |
| 2022-12-31 | $0.62B | $0.22B | 34.89% |
| 2022-09-30 | $0.80B | $0.40B | 49.56% |
| 2022-06-30 | $0.93B | $0.55B | 59.68% |
| 2022-03-31 | $0.95B | $0.63B | 66.35% |
| 2021-12-31 | $0.99B | $0.69B | 69.89% |
| 2021-09-30 | $1.04B | $0.77B | 73.94% |
| 2021-06-30 | $0.91B | $0.67B | 73.08% |
| 2021-03-31 | $0.77B | $0.57B | 73.09% |
| 2020-12-31 | $0.42B | $0.29B | 69.67% |
| 2020-09-30 | $0.14B | $0.07B | 48.89% |
| 2020-06-30 | $0.04B | $0.00B | 9.30% |
| 2020-03-31 | $0.03B | $0.00B | 5.88% |
| 2019-12-31 | $0.03B | $0.00B | 6.45% |
| 2019-09-30 | $0.03B | $0.00B | 6.90% |
| 2019-06-30 | $0.03B | 0 | 0.00% |
| 2019-03-31 | $0.02B | $0.00B | -4.55% |
| 2018-12-31 | $0.02B | $0.00B | -9.09% |
| 2018-09-30 | $0.02B | $0.00B | -20.00% |
| 2018-06-30 | $0.02B | $-0.01B | -26.32% |
| 2018-03-31 | $0.02B | $-0.01B | -26.32% |
| 2017-12-31 | $0.02B | $0.00B | -10.53% |
| 2017-09-30 | $0.02B | $0.00B | 9.52% |
| 2017-06-30 | $0.02B | $0.00B | 14.29% |
| 2017-03-31 | $0.02B | $0.00B | 20.00% |
| 2016-12-31 | $0.02B | $0.00B | 16.67% |
| 2016-06-30 | $0.01B | $0.00B | 20.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.536B | $0.283B |
| Fulgent Genetics, Inc. provides genetic testing services to physicians with clinically actionable diagnostic information. The company's technology platform integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory process which serves primarily to hospitals and medical institutions. Fulgent Genetics is headquartered in Temple City, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $38.020B | 52.51 |
| Tempus AI (TEM) | United States | $8.898B | 0.00 |
| Hims & Hers Health (HIMS) | United States | $7.354B | 118.21 |
| Inspire Medical Systems (INSP) | United States | $4.713B | 91.55 |
| IRhythm Technologies (IRTC) | United States | $3.412B | 0.00 |
| Privia Health (PRVA) | United States | $2.848B | 213.46 |
| Enovis (ENOV) | United States | $1.975B | 12.22 |
| Schrodinger (SDGR) | United States | $1.872B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.737B | 0.00 |
| Phreesia (PHR) | United States | $1.467B | 0.00 |
| Omnicell (OMCL) | United States | $1.464B | 31.58 |
| Azenta (AZTA) | United States | $1.204B | 56.04 |
| 10x Genomics (TXG) | United States | $1.011B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.568B | 0.00 |
| Talkspace (TALK) | United States | $0.517B | 307.00 |
| Veradigm (MDRX) | United States | $0.460B | 0.00 |
| Standard BioTools (LAB) | United States | $0.421B | 0.00 |
| TruBridge (TBRG) | United States | $0.389B | 0.00 |
| Claritev (CTEV) | United States | $0.363B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.277B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.209B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.203B | 0.00 |
| Pulmonx (LUNG) | United States | $0.194B | 0.00 |
| American Well (AMWL) | United States | $0.114B | 0.00 |
| EUDA Health Holdings (EUDA) | Singapore | $0.092B | 0.00 |
| Retrieve Medical Holdings (RMHI) | United States | $0.085B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.082B | 0.00 |
| CareCloud (CCLD) | United States | $0.077B | 3.33 |
| 111 (YI) | China | $0.071B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.059B | 0.00 |
| Zepp Health (ZEPP) | China | $0.039B | 0.00 |
| Outset Medical (OM) | United States | $0.038B | 0.00 |
| Zhongchao (ZCMD) | China | $0.030B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.017B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.017B | 0.00 |
| ImmunoPrecise Antibodies (IPA) | Canada | $0.014B | 0.00 |
| Streamline Health Solutions (STRM) | United States | $0.013B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.011B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.010B | 0.00 |
| Precipio (PRPO) | United States | $0.009B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.007B | 0.00 |
| Movano (MOVE) | United States | $0.006B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.005B | 0.00 |
| HeartSciences (HSCS) | United States | $0.004B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.003B | 0.00 |
| Future Health ESG (FHLT) | United States | $0.000B | 0.00 |